Search

Your search keyword '"Spyer, Moira"' showing total 213 results

Search Constraints

Start Over You searched for: Author "Spyer, Moira" Remove constraint Author: "Spyer, Moira"
213 results on '"Spyer, Moira"'

Search Results

1. Early inflammation as a footprint of increased mortality risk in infants living with HIV from three African countries

2. High mortality following early initiation of antiretroviral therapy in infants living with HIV from three African countries

3. D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years

4. Eyeglasses and risk of COVID-19 transmission—analysis of the Virus Watch Community Cohort study

5. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

6. Investigation of hospital discharge cases and SARS-CoV-2 introduction into Lothian care homes

7. Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4: 1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV

8. Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort

9. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

10. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

11. Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence

14. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells

15. Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases

16. Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study

17. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

18. Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy

19. Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ART

20. Eyeglasses and risk of COVID-19 transmission—analysis of the Virus Watch Community Cohort study

21. Early Proteomic and Innate Immunity Profiles: A Footprint of Increased Mortality Risk In Infants Living with Hiv From Three African Countries

22. Antenatal Seroprevalence of Zika and Chikungunya Viruses, Kingston Metropolitan Area, Jamaica, 2017-2019

23. Factors influencing uptake of protective behaviours by healthcare workers in England during the COVID-19 pandemic: A theory-based mixed-methods study.

24. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

26. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial

27. Sensitive HIV-1 DNA Pol Next-Generation Sequencing for the Characterisation of Archived Antiretroviral Drug Resistance

28. Cohort Profile: Virus Watch—understanding community incidence, symptom profiles and transmission of COVID-19 in relation to population movement and behaviour

31. Investigation of hospital discharge cases and SARS-CoV-2 introduction into Lothian care homes

33. Cohort Profile:Virus Watch - understanding community incidence, symptom profiles and transmission of COVID-19 in relation to population movement and behaviour

35. High Mortality Following Early Initiation of Antiretroviral Therapy in Infants Living with HIV from Three African Countries

36. Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort

38. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

39. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

40. Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning

41. COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study

44. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial

45. Influence of IL-6 levels on patient survival in COVID-19

46. Once vs twice-daily abacavir and lamivudine in African children

48. Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch)

Catalog

Books, media, physical & digital resources